Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain
暂无分享,去创建一个
Nengqin Jia | Ji-Yao Jiang | Nengqin Jia | Yinfeng Shi | Yao-hua Pan | Yong Lin | Yong Lin | Yaohua Pan | Yinfeng Shi | Xianjian Huang | Jiyao Jiang | Xianjian Huang
[1] K. Jain,et al. Nanobiotechnology-Based Drug Delivery to the Central Nervous System , 2007, Neurodegenerative Diseases.
[2] P. Kochanek,et al. Blood brain barrier permeability and acute inflammation in two models of traumatic brain injury in the immature rat: a preliminary report. , 1998, Acta neurochirurgica. Supplement.
[3] N. Soehendra,et al. N-Butyl-2-Cyanoacrylate: A Supplement to Endoscopic Sclerotherapy , 1987, Endoscopy.
[4] D. Begley,et al. Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles , 2003, Pharmaceutical Research.
[5] B. Hyman,et al. Nanoparticles enhance brain delivery of blood–brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging , 2011, Proceedings of the National Academy of Sciences.
[6] R. Hayes,et al. Nerve Growth Factor Attenuates Cholinergic Deficits Following Traumatic Brain Injury in Rats , 1997, Experimental Neurology.
[7] C. Ek,et al. Changes in blood–brain barrier permeability to large and small molecules following traumatic brain injury in mice , 2007, The European journal of neuroscience.
[8] D D Allen,et al. Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.
[9] L. Fenart,et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. , 1999, The Journal of pharmacology and experimental therapeutics.
[10] A. Vertegel,et al. Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agents , 2011, Biotechnology and bioengineering.
[11] Richard Madsen,et al. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review , 2004, Journal of Neuro-Oncology.
[12] H. Bramlett,et al. Alterations in blood-brain barrier permeability to large and small molecules and leukocyte accumulation after traumatic brain injury: effects of post-traumatic hypothermia. , 2009, Journal of neurotrauma.
[13] Peter Ramge,et al. Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.
[14] J. Ghajar. Traumatic brain injury , 2000, The Lancet.
[15] Joo-Hiuk Son,et al. Principle and applications of terahertz molecular imaging , 2013, Nanotechnology.
[16] William Couet,et al. Indirect Evidence that Drug Brain Targeting Using Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles Is Related to Toxicity , 1999, Pharmaceutical Research.
[17] W. D. de Jong,et al. Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.
[18] M. Kupersmith,et al. The effect of embolization with N-butyl cyanoacrylate prior to surgical resection of cerebral arteriovenous malformations. , 1993, Journal of neurosurgery.
[19] M. Setou,et al. Functionalized magnetic nanoparticles as an in vivo delivery system. , 2009, Methods in molecular biology.
[20] E. Hansson,et al. Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.
[21] N. Behan,et al. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. , 2001, Biomaterials.
[22] G. Fricker,et al. Delivery of nanoparticles to the brain detected by fluorescence microscopy. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[23] D. A. Kharkevich,et al. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles , 1995 .
[24] D. Stein,et al. Blood-brain barrier breakdown and edema formation following frontal cortical contusion: does hormonal status play a role? , 1995, Journal of neurotrauma.
[25] Hartwig Wolburg,et al. Tight junctions of the blood-brain barrier: development, composition and regulation. , 2002, Vascular pharmacology.
[27] D. A. Kharkevich,et al. Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.
[28] E. Neuwelt,et al. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.
[29] A. Marmarou,et al. The permissive nature of blood brain barrier (BBB) opening in edema formation following traumatic brain injury. , 2000, Acta neurochirurgica. Supplement.
[30] Jayanth Panyam,et al. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.
[31] Drug targeting to the brain. , 2007, Annual review of pharmacology and toxicology.
[32] C. Werner,et al. Pathophysiology of traumatic brain injury. , 2007, British journal of anaesthesia.
[33] Brian Y. Hwang,et al. Adjuvant Embolization With N-Butyl Cyanoacrylate in the Treatment of Cerebral Arteriovenous Malformations: Outcomes, Complications, and Predictors of Neurologic Deficits , 2009, Stroke.
[34] Y. Katayama,et al. Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. , 2006, Acta neurochirurgica. Supplement.
[35] Gordon L. Amidon,et al. The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent , 1997, Pharmaceutical Research.
[36] I. Sukhotnik,et al. Use of N-butyl-2-cyanoacrylate in elective surgical incisions--longterm outcomes. , 1999, Journal of the American College of Surgeons.
[37] J. Hainfellner,et al. Tissue reactions induced by different embolising agents in cerebral arteriovenous malformations: a histopathological follow‐up , 2006, Pathology.
[38] R. Egleton,et al. Mannitol opening of the blood–brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin , 2004, Brain Research.
[39] L. Noble,et al. Traumatic brain injury in the rat: Characterization of a lateral fluid-percussion model , 1989, Neuroscience.
[40] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[41] Ram B. Gupta,et al. Fundamentals of Drug Nanoparticles , 2006 .
[42] A. Kabanov,et al. Novel Nanomaterials for Clinical Neuroscience , 2008, Journal of Neuroimmune Pharmacology.
[43] H. Fenniri,et al. Nanotechnology-based drug delivery systems , 2007, Journal of occupational medicine and toxicology.
[44] K R Maravilla,et al. Osmotic blood-brain barrier disruption: Computerized tomographic monitoring of chemotherapeutic agent delivery , 1979 .
[45] J. Kreuter,et al. Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.